DrugCard Literature Screening


DrugCard provides full-regulatory compliant SaaS to help pharmacovigilance teams in pharma companies and CROs by trimming literature screening time and generating deeper insights about drug safety using sophisticated parsers and AI-tech. Having secured €500K from venture capitalists and with Google's support, our trajectory is set towards 100 customers and a projected ARR of €1.0M by 2024.



Key features of DrugCard:● Big database of medical and scientific literature, including more than 600 local journal sites and publications from EMA, WHO, FDA, MHRA, TGA, PMDA, Swissmedic, and local Health Authorities● Automatic article translation● Support of any journals (PDFs, scanned PDFs, HTML pages)● Automatic reports and audit trails● Advanced OCR and AI technologies● GVP / FDA CFR 21 Part 11 / GAMP5 compliant


Top benefits of the product

1. Reduces up to 70% of time spent on literature screening.
2. Accurate automatic article translations.
3. Supports any type of journal.


Why is this product incredible?

Leveraging proprietary technology, DrugCard is one of the leaders in pharma regulation, drug safety, and software innovation. A platform supporting journals from 43+ countries and scanning medical literature across 100 languages.